Mednet Logo
CommunityMedical Oncology

In a patient with inflammatory triple-positive breast cancer who has a pCR to neoadjuvant chemotherapy, but has an incidentally found focus of intermediate-grade ER+/PR+/HER2- ILC in the mastectomy specimen, how would this impact your adjuvant radiation recommendations?

Would you consider this a pCR, and would you de-escalate the dose?
3 Answers
Mednet Member
Mednet MemberInvited Expert
Radiation Oncology · Beth Israel Deaconess Medical Center
Answered on

This finding would not have any impact on my recommendations, since her management needs to be guided by the inflammatory breast cancer. That means chest wall plus nodal irradiation tailored to the findings of axillary surgery. There are no data on whether we can decrease the dose in patients with a...

Join for free or sign in to see the full answer

Mednet Member
Mednet MemberInvited Expert
Radiation Oncology · Duke University Medical Center
Answered on

Inflammatory breast cancer is an uncommon subtype with a poor prognosis and high frequency of both distant mets and local recurrence. Patients are not generally operable at presentation. NCCN guidelines call for initial systemic therapy with good responders proceeding to mastectomy followed by posto...

Join for free or sign in to see the full answer

Mednet Member
Mednet MemberInvited Expert
Radiation Oncology · Varian Medical Systems/Allegheny health network
Answered on

I would treat it like a principle for inflammatory breast cancer, where I consider a scar boost even for pCR or boost any undissected GTV nodes.

Join for free or sign in to see the full answer